本页面由Tiger Trade Technology Pte. Ltd.提供服务

康乃德生物医药

0.9057
+0.03574.10%
盘后:0.91000.0043+0.47%19:53 EDT
成交量:161.98万
成交额:148.29万
市值:5,702.64万
市盈率:-0.76
高:0.9330
开:0.9082
低:0.8800
收:0.8700
52周最高:3.82
52周最低:0.8501
股本:6,296.39万
流通股本:1,730.41万
量比:1.20
换手率:9.36%
股息:- -
股息率:- -
每股收益(TTM):-1.1933
每股收益(LYR):-1.0000
净资产收益率:-140.51%
总资产收益率:-69.75%
市净率:2.12
市盈率(LYR):-0.91

数据加载中...

2024/07/01

超过5%披露

Form SC 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]
2024/04/16

年度报告

Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
2024/02/27

超过5%披露

Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
2024/02/27

超过5%披露

Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
2024/02/13

超过5%披露

Form SC 13D - General statement of acquisition of beneficial ownership
2024/02/13

超过5%披露

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
2024/02/13

超过5%披露

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
2023/12/20

超过5%披露

Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
2023/12/19

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2023/12/19

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2023/12/14

超过5%披露

Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
2023/12/13

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2023/12/13

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2023/12/04

超过5%披露

Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend]
2023/11/28

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2023/11/28

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2023/11/22

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2023/11/22

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2023/10/05

超过5%披露

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
2023/07/24

SEC问询函

Form CORRESP - Correspondence